This article has Open Peer Review reports available.
The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia
© Künkele et al.; licensee BioMed Central Ltd. 2013
Received: 20 January 2013
Accepted: 27 September 2013
Published: 2 October 2013
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. While current treatment regimens achieve almost 80% overall survival, long-term side effects of chemotherapeutic agents can be severe. The functional BCL2-938C > A promoter polymorphism is known to influence the balance between survival and apoptosis of malignant hematolymphoid cells. We investigated its usefulness as a marker for treatment stratification for children with ALL.
We analyzed DNA from 182 children suffering from ALL in this study to determine genotypes of the−938 C > A polymorphism by “slow-down” PCR.
ALL patients with the BCL2-938CC genotype had an approximately 3-fold higher risk of belonging to a high-risk group. Within the high-risk group, 50% of BCL2-938CC patients were classified as high-risk due to poor prednisone response whereas only 33% of patients with AC and AA genotypes were classified as high-risk for the same reason.
Our results suggest that BCL2-938C > A genotyping may be beneficial for therapy response prediction in ALL patients, and warrant examination in a larger cohort to validate its usefulness for treatment stratification of pediatric ALL patients.
Leukemia is the most common pediatric cancer and the most common cause of disease-related death in childhood. Acute lymphoblastic leukemia (ALL) accounts for 80% of pediatric leukemias . The disease is characterized by uncontrolled proliferation of lymphoid progenitors in the bone marrow with consequent accumulation of malignant lymphoblasts in both bone marrow and peripheral blood. Current treatment regimens result in approximately 80% overall survival (OS) in children with ALL. However, the chemotherapeutic agents used target both malignant and non-malignant cells, and the side effects can be severe, especially for high-risk patients, who receive the most aggressive therapy [1–3]. Particularly, long-term side effects are of great interest in pediatric oncology, since these patients are treated very early in life, with many years following their disease. The identification of additional markers which would allow improved risk stratification and more individually tailored therapy regimens is highly desirable, even to lower risk of adverse long-term side effects. For the time being the most important outcome predictors are genetic subsets, initial white blood cell count, age at diagnosis, and early treatment response measured by minimal residual disease (MRD) markers . Although many genetic abnormalities are associated with clinical outcome, only few of them are routinely used for treatment stratification. These include the presence of trisomy 4, 10 or 17 or the Philadelphia chromosome. Occasionally the significance of a given prognostic factor may change with advances in treatment. For example, the outcome for pediatric ALL patients with the Philadelphia chromosome has improved substantially since tyrosine kinase inhibitors were included in the treatment regimen . Finding markers for risk stratification can improve risk group assignment and consequently improve treatment efficacy by applying as much therapy as needed to cure the patient but avoiding over-treatment, which can increase long-term adverse side effects. Bcl-2 was initially identified as an anti-apoptotic regulatory protein , but it also serves as an inhibitor of proliferation . The functional implication of Bcl-2 in tumorigenesis is ambiguous, as the anti-apoptotic effect may be oncogenic while the anti-proliferative effect appears tumor-suppressive. Which of the dual functions predominates seems to be tissue specific. This may explain why the prognostic implication of Bcl-2 expression depends on cancer type. For example, its expression is related to decreased survival in chronic lymphocytic leukemia and prostate cancer [8, 9], whereas increased Bcl-2 expression is associated with favorable outcome in colorectal and breast cancer [10, 11]. Bcl-2 may play a crucial role in the survival of hematolymphoid cells, where Bcl-2 inhibits apoptosis by preventing cytochrome c release from the mitochondria, thereby blocking caspase activation . BCL2 has two promoters with different functional properties. Transcription is driven by the P1 promoter, while the P2 promoter acts as a negative regulatory element [13, 14]. Cis alterations have been shown to increase the activity of the P2 promoter, suppressing Bcl-2 expression . The functional−938 C > A promoter polymorphism is located in the inhibitory P2 promoter region . C and A alleles of this polymorphism differentially bind transcription factors and affect promoter activity. The C allele shows altered binding of transcription factors, increased activity of inhibitory promoter P2 and therefore decreased expression of Bcl-2. In patients with lymph node-negative breast cancer, oropharyngeal squamous cell carcinoma, chronic lymphocytic leukemia, glioblastoma multiforme and prostate cancer the A allele has been associated with higher Bcl-2 expression levels and the−938 C > A polymorphism has been associated with survival of patients suffering from these cancers [16–20]. The present study investigates genotypes of the BCL2−938 C > A promoter polymorphism as potential markers for risk and treatment stratification in children with ALL.
Research followed the tenets of the Declaration of Helsinki, and was approved by the institutional review board of Children’s University Hospital Essen. The study comprised blood samples from 182 patients diagnosed with ALL and treated between January 1987 and December 2010 in the Department of Pediatric Hematology-Oncology of the University Hospital Essen according to the clinical trial protocols ALL-BFM 1990, 1995 and 2000, Interfant, EsPhALL and CoALL for which informed consent was obtained. Data were retrospectively evaluated from medical records.
Determination of BCL2−938C > A genotypes
To determine the BCL2−938 genotypes, DNA was isolated from peripheral blood by using a commercially available kit according to the manufacturer’s instructions (QIAamp, Qiagen, Hilden, Germany). Genotypes of the−938 C > A polymorphism were determined by slowdown PCR . Previously described primers were used for the region of interest: forward primer 5′-CAGCAGCTTTTCGGAAAATG-3′ and biotinylated reverse primer 5′-TATCCACGGGACCGCTTCTTCAC-3′ . The 134 bp PCR products were analyzed by pyrosequencing using the primer 5′-TCCCCGGCTCCTTCATCGTC-3′ on the PSQ96 system according to the manufacturer’s instructions (Biotage, Uppsala, Sweden), and as previously described . Results were analyzed using PSQ96 SNP software (Biotage, Uppsala, Sweden). Appropriate negative and positive controls for each genotype were included. Sequencing accuracy was verified by re-genotyping 60 samples using pyrosequencing and 10 randomly selected samples by Sanger sequencing (100% concordance with results from slowdown PCR). Slowdown PCR and pyrosequencing assays have been extensively used and validated for polymorphism genotyping in previous studies [16–18].
This study used a hypothesis-driven retrospective candidate gene approach to investigate the BCL2−938C > A polymorphism. Kaplan-Meier analyses and the log-rank test were used to retrospectively evaluate the relationship between risk group, BCL2 genotype and outcome from the date of primary diagnosis to the end of follow-up. Multiple Cox regression analyses were performed to assess the joint impact of BCL2−938C > A genotype, patient gender and age with or without risk group classification on the clinical outcome. Student’s t-test was used for genotype-dependent comparison of continuous variables. Contingency tables and Pearson’s chi-squared test were used to compare categorical variables dependent on BCL2 genotypes. AA and AC genotypes have been combined as one group to allow for odds ratio analysis and linear testing versus risk groups. Deviation from the Hardy-Weinberg equilibrium was assessed using the Hardy-Weinberg equilibrium public domain software by S. Rodriguez et al.  (http://www.oege.org/software/hwe-mr-calc.shtml). Differences with p < 0.05 were regarded as significant. Statistical analyses were conducted using SPSS 17.0 (IBM, Ehningen, Germany), or GraphPad Prism 4.0 (GraphPad Software Inc., La Jolla, CA, USA).
Clinico-pathological characteristics at primary diagnosis and genotype distribution
AC / AA
Mean age (years ± SD)
6.5 ± 4.6
6.3 ± 4.5
7.1 ± 4.6
Relapse after HSCT (n = 63)
Risk Group Classification
Prednisone response (n = 174)
Molecular genetics (n = 176)
chromosomal 9 deletion
BCL2 −938C > A genotype and ALL risk groups
AC / AA
Odds Ratio (95% CI)
High Risk patients with available prednisone response data and BCL2 -938C > A genotype
AC / AA
High risk due to poor prednisone response
Treatment of ALL involves some of the most complex chemotherapy combinations and treatment schedules used in oncology. In most patients, induction chemotherapy is initially used to reduce the burden of lymphoblasts in the bone marrow and restore normal hematopoietic function. Consolidation therapy is then used with the intention of clearing all drug-resistant leukemia cells that have survived induction therapy from the blood and bone marrow and to prevent minimal residual disease. Maintenance chemotherapy consists of two to three years of low-dose antineoplastic drugs designed to prevent leukemia relapse during the crucial few years after remission, induction and consolidation. The significant improvements in survival for children with ALL during the past two decades can be attributed to both favorable disease biology and the success of carefully designed, risk-adapted treatment. Risk stratification evolved during these decades to incorporate response to initial treatment, cytogenetics and other biological characteristics of the disease. Measurement of minimal residual disease is now used to improve risk stratification and to allocate patients to hematopoetic stem cell transplantation in many pediatric clinical trials.
In this study, we examined the BCL2−938 C > A polymorphism as possible marker for risk stratification and predicting outcome in pediatric ALL patients. The long follow-up time of more than 60 months allowed the evaluation of OS and EFS. Both were comparable to that reported for other cohorts of pediatric ALL patients with similar follow-up periods [23–25]. Since pediatric cancers are relatively rare, only those treatment centers seeing a large proportion of children with cancer are able to recruit sufficient numbers of patients for retrospective analyses of long-term follow-up events, and this takes a long time to be accomplished. The patients analyzed in our study were treated according to seven different protocols. The variety in the protocols stem from changes of trial protocols made during the long recruitment times and age-adjusted treatment regimens. This permanent change and development can complicate analyses and comparability of analyses, in addition to the small numbers of patients in subgroups with specific molecular genetics backgrounds or ALL immunophenotyping. Some limitations exist for the interpretation of the data in this study, since patients were non-uniformly treated and some results were detected in (exploratory) subgroup analysis, in which some subgroups contained small number of patients. The effect of the BCL2−938 C > A promoter polymorphism should be assessed in a larger independent cohort of, optimally, uniformly treated patients.
The patient genotype of the BCL2−938C > A polymorphism was significantly correlated with risk stratification, but not with outcome or the clinical risk markers examined. As expected, risk groups were significantly correlated with OS and EFS, so that patients belonging to the low-risk groups had a significantly better outcome than the patients belonging to the medium-or high-risk groups [26, 27]. This supports that patients belonging to a higher risk group require a more intensive treatment regimen. Since more intensive treatment regimens can cause severe side effects and/or long-term adverse affects, additional markers to improve selection of the best treatment regimen have the power to reduce both short-and long-term adverse patient effects. Bcl-2 is known to be a possible indicator for therapy response during induction chemotherapy treatment of adult patients with ALL , and Bcl-2 inhibition in combination with methadone increases the induction of apoptosis in pediatric ALL cells . In our study, the−938 C > A BCL2 promoter polymorphism did not correlate with OS or EFS and is on its own not predictive of outcome of pediatric ALL patients, but we detected an influence of the BCL2−938 C > A polymorphism on risk stratification. In our cohort, the risk of a child with a CC genotype to be in a specific risk group increased significantly and linearly from the standard-to high-risk groups, and vice versa, decreased linearly for patients with either AA or AC genotypes. In an exploratory analysis, poor therapy response, and especially response to prednisone was the main reason for classification of BCL2−938 CC patients into the high-risk group, although their overall outcome was not worse than the outcome of patients belonging to standard-or medium-risk groups. Since it is known that prednisone treatment decreases Bcl-2 expression and ALL patients are routinely treated with prednisone, this polymorphism should be assessed in ALL patients . Furthermore, Bcl-2 is an interesting drug target with different inhibitors under evaluation and the polymorphism identified here would be an interesting candidate to investigate its putative biomarker properties [31, 32].
Our results suggest that BCL2−938 C > A genotyping may be beneficial for predicting therapy response in ALL patients. This polymorphism should be examined in a larger independent (prospective) cohort to verify the connection between risk and genotype and validate its usefulness for treatment stratification of pediatric ALL patients with regard to its possible interaction with prednisone response.
We thank B. Remus, S. Büscher and G. Müller for excellent assistance. The authors thank the WTZ Research Support Service (supported in part by the Deutsche Krebshilfe Comprehensive Cancer Center financing) for comments on and editing of the manuscript.
- Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med. 2004, 350 (15): 1535-1548. 10.1056/NEJMra023001.View ArticlePubMedGoogle Scholar
- Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, Neale G, Howard SC, Evans WE, Pui CH, et al: Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011, 117 (8): 2340-2347. 10.1182/blood-2010-10-311969. quiz 2556View ArticlePubMedPubMed CentralGoogle Scholar
- Morimoto A, Imamura T, Ishii R, Nakabayashi Y, Nakatani T, Sakagami J, Yamagami T: Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic. Cancer. 2008, 113 (6): 1362-1369. 10.1002/cncr.23716.View ArticlePubMedGoogle Scholar
- Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, et al: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009, 360 (26): 2730-2741. 10.1056/NEJMoa0900386.View ArticlePubMedPubMed CentralGoogle Scholar
- Ravandi F, Kebriaei P: Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009, 23 (5): 1043-1063. 10.1016/j.hoc.2009.07.007. viView ArticlePubMedPubMed CentralGoogle Scholar
- Cory S, Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002, 2 (9): 647-656.View ArticlePubMedGoogle Scholar
- Zinkel S, Gross A, Yang E: BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 2006, 13 (8): 1351-1359. 10.1038/sj.cdd.4401987.View ArticlePubMedGoogle Scholar
- Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O’Brien S, Garcia-Manero G, Manshouri T, Albitar M: Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2002, 16 (6): 1045-1052. 10.1038/sj.leu.2402540.View ArticlePubMedGoogle Scholar
- Keshgegian AA, Johnston E, Cnaan A: Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol. 1998, 110 (4): 443-449.View ArticlePubMedGoogle Scholar
- Ofner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Totsch M, Bocker W, Jasani B, Schmid KW: Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer. 1995, 72 (4): 981-985. 10.1038/bjc.1995.446.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang GJ, Kimijima I, Tsuchiya A, Abe R: The role of bcl-2 expression in breast carcinomas (Review). Oncol Rep. 1998, 5 (5): 1211-1216.PubMedGoogle Scholar
- Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol. 1994, 124 (1-2): 1-6.View ArticlePubMedGoogle Scholar
- Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P, Korsmeyer SJ: Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J. 1988, 7 (1): 123-131.PubMedPubMed CentralGoogle Scholar
- Young RL, Korsmeyer SJ: A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol. 1993, 13 (6): 3686-3697.View ArticlePubMedPubMed CentralGoogle Scholar
- Park BL, Kim LH, Cheong HS, Cho HY, Kim EM, Shin HD, Kim YS, Lee C: Identification of variants in cyclin D1 (CCND1) and B-Cell CLL/lymphoma 2 (BCL2). J Hum Genet. 2004, 49 (8): 449-454.View ArticlePubMedGoogle Scholar
- Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, Schmid KW, Siffert W, Kimmig R: The AA genotype of the regulatory BCL2 promoter polymorphism (938C > A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res. 2007, 13 (19): 5790-5797. 10.1158/1078-0432.CCR-06-2673.View ArticlePubMedGoogle Scholar
- Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nuckel H, Lang S, Schmid KW, Siffert W, Bachmann HS: The regulatory BCL2 promoter polymorphism (−938C > A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol. 2009, 20 (6): 1094-1099. 10.1093/annonc/mdn763.View ArticlePubMedGoogle Scholar
- Nuckel H, Frey UH, Bau M, Sellmann L, Stanelle J, Durig J, Jockel KH, Duhrsen U, Siffert W: Association of a novel regulatory polymorphism (−938C > A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007, 109 (1): 290-297. 10.1182/blood-2006-03-007567.View ArticlePubMedGoogle Scholar
- El Hindy N, Bachmann HS, Lambertz N, Adamzik M, Nuckel H, Worm K, Zhu Y, Sure U, Siffert W, Sandalcioglu IE: Association of the CC genotype of the regulatory BCL2 promoter polymorphism (−938C > A) with better 2-year survival in patients with glioblastoma multiforme. J Neurosurg. 2011, 114 (6): 1631-1639. 10.3171/2010.12.JNS10478.View ArticlePubMedGoogle Scholar
- Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P, Buettner R, Nuckel H, Eisenhardt A, Rubben H, Schmid KW, et al: Regulatory BCL2 promoter polymorphism (−938C > A) is associated with adverse outcome in patients with prostate carcinoma. Int J Cancer. 2011, 129 (10): 2390-2399. 10.1002/ijc.25904.View ArticlePubMedGoogle Scholar
- Bachmann HS, Siffert W, Frey UH: Successful amplification of extremely GC-rich promoter regions using a novel ‘slowdown PCR’ technique. Pharmacogenetics. 2003, 13 (12): 759-766. 10.1097/00008571-200312000-00006.View ArticlePubMedGoogle Scholar
- Rodriguez S, Gaunt TR, Day IN: Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. 2009, 169 (4): 505-514.View ArticlePubMedPubMed CentralGoogle Scholar
- Khalid S, Moiz B, Adil SN, Khurshid M: Retrospective review of pediatric patients with acute lymphoblastic leukemia: a single center experience. Indian J Pathol Microbiol. 2010, 53 (4): 704-710. 10.4103/0377-4929.72044.View ArticlePubMedGoogle Scholar
- Davies SM, Mehta PA: Pediatric acute lymphoblastic leukemia: is there still a role for transplant?. Hematology Am Soc Hematol Educ Program. 2010, 2010: 363-367. 10.1182/asheducation-2010.1.363.PubMedGoogle Scholar
- Foa R: Acute lymphoblastic leukemia: age and biology. Pediatr Rep. 2011, 3 (Suppl 2): e2-View ArticlePubMedPubMed CentralGoogle Scholar
- Hoelzer D, Gokbuget N, Ottmann O, Pui CH, Relling MV, Appelbaum FR, Van Dongen JJ, Szczepanski T: Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2002, 2002: 162-192. 10.1182/asheducation-2002.1.162.Google Scholar
- Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, Van Wering ER, Van Weerden JF, Hermans J, Slater R, van den Berg E, et al: BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia. 2002, 16 (6): 1099-1111. 10.1038/sj.leu.2402489.View ArticlePubMedGoogle Scholar
- Chauhan PS, Bhushan B, Singh LC, Mishra AK, Saluja S, Mittal V, Gupta DK, Kapur S: Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy. Exp Mol Pathol. 2012, 92 (1): 44-49. 10.1016/j.yexmp.2011.09.004.View ArticlePubMedGoogle Scholar
- Singh A, Jayanthan A, Farran A, Elwi AN, Kim SW, Farran P, Narendran A: Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition. Leuk Res. 2011, 35 (12): 1649-1657. 10.1016/j.leukres.2011.06.035.View ArticlePubMedGoogle Scholar
- Casale F, Addeo R, D’Angelo V, Indolfi P, Poggi V, Morgera C, Crisci S, Di Tullio MT: Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia. Int J Oncol. 2003, 22 (1): 123-128.PubMedGoogle Scholar
- High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O’Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB: The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 2010, 77 (3): 483-494. 10.1124/mol.109.060780.View ArticlePubMedGoogle Scholar
- Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S: Inhibition of Bcl-2 anti-apoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood. 2012, 119 (25): 6089-6098. 10.1182/blood-2011-09-378141.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/452/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.